3
Views
21
CrossRef citations to date
0
Altmetric
Original Article

Clinical Significance of Serum Type-III Procollagen Arninopropeptide in Hepatitis B Virus-Related Liver Diseases

, , , , , , , & show all
Pages 533-538 | Received 24 Oct 1988, Accepted 09 Jan 1989, Published online: 08 Jul 2009
 

Abstract

Serum type-III procollagen aminopropeptide (PIIIP) has been considered a marker of hepatic fibrogenesis. In an attempt to evaluate the clinical significance of serum PIIIP in patients with hepatitis B virus (HBV)-related liver diseases, the levels of the peptide were measured in 66 healthy adults and 200 patients with HBV-related liver diseases. As compared with the healthy adults (12.3 ± 3.1 ng/ml), the serum PIIIP levels were significantly elevated in patients with acute hepatitis (17.4 ± 6.6 ng/ml), chronic persistent hepatitis (18.3 ± 4.9 ng/ml), and inactive liver cirrhosis (22.1 ± 7.1 ng/ml). The PIIIP levels in patients with chronic active hepatitis (CAH) (33.9 ± 23.1 ng/ml) were the highest among HBV-related liver diseases and had a tendency to increase with the severity of CAH. Of the liver-diseased patients with serum PIIIP levels greater than 30 ng/ml, 91% had a recent episode of severe hepatocellular damage, whereas 56% of patients with greatly elevated serum liver aminotransferase levels had no associated high increase in serum PIIIP levels. Thus, we suggest that fibrogenesis in HBV-related liver diseases is initiated by severe hepatocellular damage, but liver damage can also take place without prominent hepatic fibrogenesis. Serum PIIIP may be a serum marker to predict the active fibrogenesis of HBV-related liver diseases.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.